


9. Canbay A, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. *Lab Invest* 2003; 83: 655–663.
10. Kocabayoglu P, Friedman SL. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. *Front Biosci (Schol Ed)* 2013; 5: 217–230.
11. Schuppan D, et al. Matrix as a modulator of hepatic fibrogenesis. *Semin Liver Dis* 2001; 21: 351–372.
12. Trautwein C, et al. Hepatic fibrosis: Concept to treatment. *J Hepatol* 2015; 62: (1 Suppl): S15–S24.
13. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *World J Gastroenterol* 2014; 20: 475–485.
14. Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; 41: 1313–1321.
15. Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. *World J Gastroenterol* 2016; 22: 1711–1720.
16. Angulo P, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* 1999; 30: 1356–1362.
17. Wai CT, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; 38: 518–526.
18. Vallet-Pichard A, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. *Hepatology* 2007; 46: 32–36.
19. Angulo P, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 2007; 45: 846–854.
20. Guechot J, et al. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. *Clin Chim Acta* 2010; 411: 86–91.
21. Guha IN, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. *Hepatology* 2008; 47: 455–460.
22. Bansal MB, Chamroonkul N. Antifibrotics in liver disease: are we getting closer to clinical use? *Hepatology* 2018; in press; online <https://doi.org/10.1007/s12072-018-9897-3>.
23. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. *Therap Adv Gastroenterol* 2011; 4: 391–417.
24. Marcellin P, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013; 381: 468–475.
25. Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol* 2017; 67: 829–846.
26. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. *J Clin Invest* 2013; 123: 1887–1901.

Navštivte nový web časopisu Anesteziologie a intenzivní medicína



www.aimjournal.cz

› **veškeré informace o časopisu**
přehledně a pohromadě
(včetně informací o předplatném
a pokynů pro autory)

› **archiv článků**

› **rejstřík autorů** s přehledem
všech prací publikovaných
v časopise

› **přístup do redakčního**
systemu pro autory, recenzenty,
redakční radu



INFORMACE PRO PŘEDPLATITELE

K aktuálním článkům v pdf se dostanete pouze jako předplatitelé
pomocí přihlašovacích údajů **JMÉNO: predplatne HESLO: aimjournal**